Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

WOUNDCOM

Financiado

Interactive biomembranes for wound management exploiting the unique wound heal...

Interactive biomembranes for wound management exploiting the unique wound healing and antimicrobial properties of human collagen VI This project's objective is to develop a wound dressing product that will address the unmet needs of patients with chronic wounds. The prevalence of chronic wounds is increasing and results in a growing utilization of healthcare a... ver más

31/01/2019

COLZYX AB

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

COLZYX AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-01-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 6 años

0% 70% 100%

2 Participantes

COLZYX AB

50.00K€ | Lider

EKOTEK INGENIERIA Y CONSULTO...

527.89K€ | Participante

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 6 meses Fecha Inicio: 2018-07-13
Fecha Fin: 2019-01-31

Líder del proyecto

COLZYX AB

TRL 4-5

Presupuesto del proyecto 71K€

Descripción del proyecto This project's objective is to develop a wound dressing product that will address the unmet needs of patients with chronic wounds. The prevalence of chronic wounds is increasing and results in a growing utilization of healthcare and financial resources. The available wound care options can manipulate one or multiple aspects of the wound environment, but cannot form antibacterial barriers and facilitate healing to a satisfactory level at the same time. Colzyx aims to address this challenge by developing an innovative wound dressing product that will make use of the newlydiscovered healing and antimicrobial properties of human collagen VI. It is first-in-class product which uses highly functional molecules from the human innate immune system in wound management. This novel technology combines these potent molecules with a biomembrane – established in wound management market. Together, they effectively enhance wound closure and fight bacterial infection simultaneously. This approach offers significant benefits to patients by reducing pain and discomfort, and accelerating recovery. It will also shorten hospitalisation time and decrease labour for healthcare professionals and the financial burden. Comparing to available wound dressings, Colzyx’s product is unique and will address a new market category of interactive biomembranes. The ultimate success will depend on the quality of confirmatory data and agreement with development partner to share the challenges of subsequent research and market introduction. Colzyx plans to take the product through the CE-mark registration study and reach the market through an agreement with a strong defined licence partner. The problem of pathogenic resistance to drugs is growing and highlighted by the national and international health organisations. This adds to the significance of the challenge posed by chronic wounds and ensures Colzyx in the endeavour of developing and bringing to the market its novel wound dressing.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores